Moleculin Biotech receives Notice of Intent to Grant European patent for Annamycin (naxtarubicin)

Moleculin Biotech, Inc.

• European patent covers method of making preliposomal Annamycin lyophilizate with improved stability and high purity.
• Base patent term extends until 2040, subject to extension for regulatory approval.
• Annamycin (naxtarubicin) is a potential first non-cardiotoxic anthracycline, targeting AML and STS lung mets.
• Company has additional pending patent applications in US, Europe, and other jurisdictions.
• Grant subject to payment of fees and completion of final formalities.